Stocks

JPMorgan Chase Initiates Neutral Rating on Nektar Therapeutics

Guavy AI Editorial Team Published August 22, 2026

Instruments

JPM

Nektar Therapeutics, a biopharmaceutical company, has received coverage from JPMorgan Chase & Co., which initiated a neutral rating and set a price target of $65.00 on its stock.

This is not the first time Nektar Therapeutics has been covered by analysts. Several firms have issued reports on the company's stock in recent weeks, with some raising their price targets while others maintained or lowered theirs.

According to data from MarketBeat.com, ten investment analysts have rated the stock as a Buy, two as Hold, and one as Sell. The average rating is Moderate Buy with a consensus target price of $141.50.

JPMorgan Chase Initiates Neutral Rating on Nektar Therapeutics

Honeywell Workers on Teesside Vote on Strike Action Over Pension Cuts

Honeywell Aerospace Listing Draws Attention, Analysts Predict 35 Percent Increase

Honeywell Rated Buy on Strong Order Growth, Margin Expansion